News | Heart Valve Technology | April 20, 2017

Alabama Medical Center First in Southeast to Offer CoreValve Evolut Pro TAVR Device

Technology includes self-expanding implant with advanced sealing for treatment of severe aortic stenosis

Alabama Medical Center First in Southeast to Offer CoreValve Evolut Pro TAVR Device

April 20, 2017 — The Structural Heart Program at Princeton Baptist Medical Center, (Birmingham, Ala.) recently became the first center in the Southeast to implant the newly U.S. Food and Drug Administration (FDA)-approved CoreValve Evolut Pro.

The transcatheter aortic valve replacement (TAVR) device is indicated for the treatment of severe aortic stenosis for symptomatic patients who are at high or extreme risk for open-heart surgery. Recently unveiled clinical data showed high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics for the self-expanding valve.

Aortic stenosis is a common and serious condition that occurs when the heart’s aortic valve narrows, restricting blood flow from the heart to the aorta, which can severely weaken the heart muscle. If left untreated, it can lead to heart failure and even death. Mustafa Ahmed, M.D., director of the Structural Heart Disease Program at Princeton Baptist Medical Center, Clifton Lewis, M.D., cardiac surgeon at Princeton, and their team have performed several hundred cases involving TAVR .   

“One of our strongest areas of expertise is treating patients with aortic stenosis who likely could not undergo open-heart surgery. We have performed several hundred TAVR procedures,” said Ahmed. “As established leaders in the field of cardiac surgery and advancing the field through research and the use of cutting-edge technology, we continue to strive to advance new minimally invasive treatments for our patients and surrounding communities.”

The Evolut Pro device features a unique valve design with an outer wrap that adds surface area contact between the valve and the native aortic annulus to further advance valve sealing performance. The biocompatible porcine pericardial tissue wrap, in addition to other design elements, is incorporated to address the occurrence of blood leaking through the sides of the valve. It is both recapturable and repositionable, so accuracy in placement and control during the procedure is increased.

The Evolut Pro System is delivered through the EnVeo R Delivery Catheter System and is indicated for vessels down to 5.5 mm. The EnVeo R system features an InLine Sheath that makes it the lowest delivery platform currently on the market, according to Medtronic. It also provides a greater opportunity to treat patients with smaller vessels through the preferred transfemoral access route.

For more information:

Related Content

BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
heart valve regurgitation seen on an echocardiogram, cardiac ultrasound, from ASE study
News | Cardiovascular Ultrasound| June 16, 2017
June 15, 2017 – While much attention has been focused on ways to lower heart disease-related injuries and deaths, the
Mitral Valve regurgitation showed on an echocardiogram, cardiac ultrasound

Mitral valve regurgitation showed on an echocardiogram. Image from Toshiba.

News | Heart Valve Technology| June 15, 2017
June 15, 2017 — 4C Medical Technologies Inc., a developer of minimally invasive therapies for structural heart diseas
Sponsored Content | Videos | Heart Valve Technology| June 14, 2017
A discussion with Rebecca Hahn, M.D., FASE, director of interventional echocardiography and professor of medicine at

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.


News | Stem Cell Therapies| June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
FDA clears Claret Medical Sentinel embolic protection device for TAVR
Feature | Heart Valve Technology| June 09, 2017
June 5, 2017 – The U.S.
Sapien 3 valve for VIV (valve in valve) procedures cleared by FDA
Feature | Heart Valve Technology| June 06, 2017 | Dave Fornell
The U.S. Food and Drug Administration (FDA) has granted market clearance for aortic and mitral valve-in-valve...
LivaNova Announces Positive Data for Perceval Sutureless Valve at AATS 2017
News | Heart Valve Technology| May 31, 2017
LivaNova PLC recently announced the presentation of data from multiple studies demonstrating the safety and...
News | Guidewires| May 30, 2017
A Canadian cardiologist has published a report in the journal Eurointervention describing how he used a Canadian-...
Overlay Init